The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Antibiotics in the clinical pipeline at the end of 2015
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The antibiotic resistance crisis: part 1: causes and threats.
Ventola, C. L. (2015) · PubMed · Cited by 4,516
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
A new antibiotic kills pathogens without detectable resistance
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., Mueller, A., Schäberle, T. F., Hughes, D. E., Epstein, S., et al. (2015) · Nature · doi:10.1038/nature14098 · Cited by 2,428
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
The Antimicrobial Resistance Crisis: Causes, Consequences, and Management
Michael, C. A., Dominey-Howes, D., & Labbate, M. (2014) · Frontiers in Public Health · doi:10.3389/fpubh.2014.00145 · Cited by 974
Alternatives to antibiotics—a pipeline portfolio review
Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V. A., Foster, S., Gilmore, B. F., Hancock, R. E. W., Harper, D., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00466-1 · Cited by 848
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 751
Clavulanic Acid: a Beta-Lactamase-Inhibiting Beta-Lactam from Streptomyces clavuligerus
Reading, C., & Cole, M. (1977) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.11.5.852 · Cited by 739
Update on the antibiotic resistance crisis
Rossolini, G. M., Arena, F., Pecile, P., & Pollini, S. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.09.006 · Cited by 695
Antimicrobial resistance in humans, livestock and the wider environment
Woolhouse, M., Ward, M., van Bunnik, B., & Farrar, J. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0083 · Cited by 678
PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Singh, R., Manjunatha, U., Boshoff, H. I. M., Ha, Y. H., Niyomrattanakit, P., Ledwidge, R., Dowd, C. S., Lee, I. Y., Kim, P., Zhang, L., et al. (2008) · Science · doi:10.1126/science.1164571 · Cited by 628
ESKAPEing the labyrinth of antibacterial discovery
Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I., & Miller, A. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4572 · Cited by 608
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3262 · Cited by 603
Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa
Srinivas, N., Jetter, P., Ueberbacher, B. J., Werneburg, M., Zerbe, K., Steinmann, J., Van der Meijden, B., Bernardini, F., Lederer, A., Dias, R. L. A., et al. (2010) · Science · doi:10.1126/science.1182749 · Cited by 554
Tew, G. N., Scott, R. W., Klein, M. L., & DeGrado, W. F. (2010) · Accounts of Chemical Research · doi:10.1021/ar900036b · Cited by 552
Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205073109 · Cited by 545
Kokryakov, V. N., Harwig, S. S. L., Panyutich, E. A., Shevchenko, A. A., Aleshina, G. M., Shamova, O. V., Korneva, H. A., & Lehrer, R. I. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80175-t · Cited by 518
Cooper, M. A., & Shlaes, D. (2011) · Nature · doi:10.1038/472032a · Cited by 474
Self-citationCombating Multidrug‐Resistant Bacteria: Current Strategies for the Discovery of Novel Antibacterials
O'Connell, K. M. G., Hodgkinson, J. T., Sore, H. F., Welch, M., Salmond, G. P. C., & Spring, D. R. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201209979 · Cited by 435
Antibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 433
Self-citationNaturally-occurring beta-lactamase inhibitors with antibacterial activity
BROWN, A. G., BUTTERWORTH, D., COLE, M., HANSCOMB, G., HOOD, J. D., READING, C., & ROLINSON, G. N. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.668 · Cited by 399
Wagenlehner, F. M., Umeh, O., Steenbergen, J., Yuan, G., & Darouiche, R. O. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62220-0 · Cited by 388
Quinolones: Action and Resistance Updated
Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., & Zhao, X. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630947 · Cited by 376
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 372
Therapeutic strategies to combat antibiotic resistance
Brooks, B. D., & Brooks, A. E. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.027 · Cited by 367
Prokocimer, P., De Anda, C., Fang, E., Mehra, P., & Das, A. (2013) · JAMA · doi:10.1001/jama.2013.241 · Cited by 361
Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?
Brown, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4675 · Cited by 359
New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin
Zhanel, G. G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2010) · Drugs · doi:10.2165/11534440-000000000-00000 · Cited by 352
The mechanism of action of PA-824: Novel insights from transcriptional profiling
Manjunatha, U., Boshoff, H. I. M., & Barry, C. E. (2009) · Communicative & Integrative Biology · doi:10.4161/cib.2.3.7926 · Cited by 319
De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers
Choi, S., Isaacs, A., Clements, D., Liu, D., Kim, H., Scott, R. W., Winkler, J. D., & DeGrado, W. F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811818106 · Cited by 308
The antibiotic resistance crisis: part 2: management strategies and new agents.
Ventola, C. L. (2015) · PubMed · Cited by 306
Glycopeptide antibiotics: Back to the future
Butler, M. S., Hansford, K. A., Blaskovich, M. A. T., Halai, R., & Cooper, M. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.111 · Cited by 303
Self-citationAarestrup, F. M. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0085 · Cited by 298
Mechanism of action of oritavancin and related glycopeptide antibiotics
Allen, N. (2003) · FEMS Microbiology Reviews · doi:10.1016/s0168-6445(02)00144-4 · Cited by 276
Antibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Self-citationInhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway
Lu, H., & Tonge, P. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700156e · Cited by 254
Kohira, N., West, J., Ito, A., Ito-Horiyama, T., Nakamura, R., Sato, T., Rittenhouse, S., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01695-15 · Cited by 247
Synthesis and Spectrum of the Neoglycoside ACHN-490
Aggen, J. B., Armstrong, E. S., Goldblum, A. A., Dozzo, P., Linsell, M. S., Gliedt, M. J., Hildebrandt, D. J., Feeney, L. A., Kubo, A., Matias, R. D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00572-10 · Cited by 243
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Coleman, K. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.026 · Cited by 241
Sutcliffe, J. A., O'Brien, W., Fyfe, C., & Grossman, T. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01288-13 · Cited by 235
Photodynamic Effects of Novel XF Porphyrin Derivatives on Prokaryotic and Eukaryotic Cells
Maisch, T., Bosl, C., Szeimies, R.-M., Lehn, N., & Abels, C. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1542-1552.2005 · Cited by 232
Antibiotic resistance sweeping developing world
Reardon, S. (2014) · Nature · doi:10.1038/509141a · Cited by 230
Helping Chemists Discover New Antibiotics
Blaskovich, M. A. T., Zuegg, J., Elliott, A. G., & Cooper, M. A. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00044 · Cited by 229
Self-citationPage, M. G. P., Dantier, C., & Desarbre, E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01525-09 · Cited by 227
Lee, R. E., Protopopova, M., Crooks, E., Slayden, R. A., Terrot, M., & Barry, C. E. (2003) · Journal of Combinatorial Chemistry · doi:10.1021/cc020071p · Cited by 207
Locke, J. B., Hilgers, M., & Shaw, K. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00871-09 · Cited by 205
Li, W., Upadhyay, A., Fontes, F. L., North, E. J., Wang, Y., Crans, D. C., Grzegorzewicz, A. E., Jones, V., Franzblau, S. G., Lee, R. E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03229-14 · Cited by 202
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
Zhanel, G. G., Lawson, C. D., Zelenitsky, S., Findlay, B., Schweizer, F., Adam, H., Walkty, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.25 · Cited by 201
Tackling the threat of antimicrobial resistance: from policy to sustainable action
Shallcross, L. J., Howard, S. J., Fowler, T., & Davies, S. C. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0082 · Cited by 196
Ito, A., Kohira, N., Bouchillon, S. K., West, J., Rittenhouse, S., Sader, H. S., Rhomberg, P. R., Jones, R. N., Yoshizawa, H., Nakamura, R., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv402 · Cited by 192
Zhanel, G. G., Love, R., Adam, H., Golden, A., Zelenitsky, S., Schweizer, F., Gorityala, B., Lagacé-Wiens, P. R. S., Rubinstein, E., Walkty, A., et al. (2015) · Drugs · doi:10.1007/s40265-015-0352-7 · Cited by 187
In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitor
Bonnefoy, A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh358 · Cited by 185
Mining the microbial dark matter
Lok, C. (2015) · Nature · doi:10.1038/522270a · Cited by 183
Morinaka, A., Tsutsumi, Y., Yamada, M., Suzuki, K., Watanabe, T., Abe, T., Furuuchi, T., Inamura, S., Sakamaki, Y., Mitsuhashi, N., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv166 · Cited by 183
Kang, S., Kim, R. Y., Seo, M. J., Lee, S., Kim, Y. M., Seo, M., Seo, J. J., Ko, Y., Choi, I., Jang, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5003606 · Cited by 178
Two decades of imipenem therapy
Rodloff, A. C., Goldstein, E. J. C., & Torres, A. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl354 · Cited by 171
Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents
Payne, D. J., Miller, W. H., Berry, V., Brosky, J., Burgess, W. J., Chen, E., DeWolf, W. E., Fosberry, A. P., Greenwood, R., Head, M. S., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.10.3118-3124.2002 · Cited by 170
In Vitro and In Vivo Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline
Macone, A. B., Caruso, B. K., Leahy, R. G., Donatelli, J., Weir, S., Draper, M. P., Tanaka, S. K., & Levy, S. B. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01242-13 · Cited by 170
A Synthetic Antimicrobial Peptidomimetic (LTX 109): Stereochemical Impact on Membrane Disruption
Isaksson, J., Brandsdal, B. O., Engqvist, M., Flaten, G. E., Svendsen, J. S. M., & Stensen, W. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200450h · Cited by 169
Oritavancin: Mechanism of Action
Zhanel, G. G., Schweizer, F., & Karlowsky, J. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir920 · Cited by 167
Sources of Antimicrobial Resistance
Woolhouse, M. E. J., & Ward, M. J. (2013) · Science · doi:10.1126/science.1243444 · Cited by 165
Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic
Grossman, T. H., Starosta, A. L., Fyfe, C., O'Brien, W., Rothstein, D. M., Mikolajka, A., Wilson, D. N., & Sutcliffe, J. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06187-11 · Cited by 162
Howarth, T. T., Brown, A. G., & King, T. J. (1976) · J. Chem. Soc., Chem. Commun. · doi:10.1039/c3976000266b · Cited by 162
Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline
Draper, M. P., Weir, S., Macone, A., Donatelli, J., Trieber, C. A., Tanaka, S. K., & Levy, S. B. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01066-13 · Cited by 158
Surveillance of antibiotic resistance
Johnson, A. P. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0080 · Cited by 156
Nonmedical Uses of Antibiotics: Time to Restrict Their Use?
Meek, R. W., Vyas, H., & Piddock, L. J. V. (2015) · PLoS Biology · doi:10.1371/journal.pbio.1002266 · Cited by 154
Piperacillin–tazobactam: a β-lactam/β-lactamase inhibitor combination
Gin, A. S., Dilay, L., Karlowsky, J. A., Walkty, A. J., Rubinstein, E., & Zhanel, G. G. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.3.365 · Cited by 153
Are pleuromutilin antibiotics finally fit for human use?
Novak, R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06219.x · Cited by 151
Stachyra, T., Péchereau, M.-C., Bruneau, J., Claudon, M., Frère, J., Miossec, C., Coleman, K., & Black, M. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00568-10 · Cited by 145
Haver, H. L., Chua, A. C. Y., Ghode, P. B., Lakshminarayana, S. B., Singhal, A., Mathema, B., Wintjens, R. T., & Bifani, P. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00308-15 · Cited by 144
In Vitro and In Vivo Activities of a New Cephalosporin, FR264205, against Pseudomonas aeruginosa
Takeda, S., Nakai, T., Wakai, Y., Ikeda, F., & Hatano, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00860-06 · Cited by 140
Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent
Im, W. B., Choi, S. H., Park, J., Choi, S. H., Finn, J., & Yoon, S. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.014 · Cited by 139
The pleuromutilin antibiotics: a new class for human use.
Novak, R., & Shlaes, D. M. (2010) · PubMed · Cited by 135
Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus
Kim, S. J., Cegelski, L., Stueber, D., Singh, M., Dietrich, E., Tanaka, K. S. E., Parr, T. R., Far, A. R., & Schaefer, J. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.01.031 · Cited by 134
Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline
Honeyman, L., Ismail, M. Y., Nelson, M. L., Bhatia, B., Bowser, T. E., Chen, J. H., Mechiche, R., Ohemeng, K. A., Verma, A. K., Cannon, E. P., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01536-15 · Cited by 134
Owen, J. G., Reddy, B. V. B., Ternei, M. A., Charlop–Powers, Z., Calle, P. Y., Kim, J. H., & Brady, S. F. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222159110 · Cited by 131
New β‐lactam–β‐lactamase inhibitor combinations in clinical development
Shlaes, D. M. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12010 · Cited by 130
Xiao, X.-Y., Hunt, D. K., Zhou, J., Clark, R. B., Dunwoody, N., Fyfe, C., Grossman, T. H., O’Brien, W. J., Plamondon, L., Rönn, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201465w · Cited by 126
A Concise Synthesis of a β-Lactamase Inhibitor
Mangion, I. K., Ruck, R. T., Rivera, N. R., Huffman, M. A., & Shevlin, M. (2011) · Organic Letters · doi:10.1021/ol202195n · Cited by 125
A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin
Guskey, M. T., & Tsuji, B. T. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.1.80 · Cited by 123
Belley, A. C., McKay, G. A., Arhin, F. F., Sarmiento, I., Beaulieu, S., Fadhil, I., Parr, T. R., & Moeck, G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00760-10 · Cited by 120
Kaplan, N., Albert, M., Awrey, D. E., Bardouniotis, E., Berman, J., Clarke, T. E., Dorsey, M., Hafkin, B., Ramnauth, J., Romanov, V., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01411-12 · Cited by 120
Walkty, A. J., Adam, H. J., Baxter, M. R., Denisuik, A. J., Lagacé-Wiens, P. R. S., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02744-13 · Cited by 116
LUCASTI, C. J., Hershberger, E., Miller, B. W., Yankelev, S., Steenbergen, J. N., Friedland, I. R., & Solomkin, J. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00049-14 · Cited by 114
Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic
Burdette, S. D., & Trotman, R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ501 · Cited by 110
Crandon, J. L., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01989-12 · Cited by 108
A Novel Macrolide Solithromycin Exerts Superior Anti-inflammatory Effect via NF-κB Inhibition
Kobayashi, Y., Wada, H., Rossios, C., Takagi, D., Higaki, M., Mikura, S., Goto, H., Barnes, P. J., & Ito, K. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.200733 · Cited by 103
Nilsson, A. C., Janson, H., Wold, H., Fugelli, A., Andersson, K., Håkangård, C., Olsson, P., & Olsen, W. M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03513-14 · Cited by 103
N -Chloramines, a Promising Class of Well-Tolerated Topical Anti-Infectives
Gottardi, W., Debabov, D. V., & Nagl, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02132-12 · Cited by 101
Locher, H. H., Seiler, P. J., Chen, X., Schroeder, S., Pfaff, P., Enderlin, M., Klenk, A., Fournier, E., Hubschwerlen, C., Ritz, D., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01830-13 · Cited by 98
Farrell, D. J., Robbins, M. J., Rhys‐Williams, W., & Love, W. G. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-10 · Cited by 98
Galani, I., Souli, M., Daikos, G. L., Chryssouli, Z., Poulakou, G., Psichogiou, M., Panagea, T., Argyropoulou, A., Stefanou, I., Plakias, G., et al. (2012) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000015 · Cited by 96
Ooi, N., Miller, K., Randall, C. P., Rhys‐Williams, W., Love, W. C., & Chopra, I. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp409 · Cited by 94
XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity
Ooi, N., Miller, K., Hobbs, J. K., Rhys‐Williams, W., Love, W. C., & Chopra, I. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp299 · Cited by 92
Confronting the challenges of discovery of novel antibacterial agents
Singh, S. B. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.053 · Cited by 92
Livermore, D. M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt118 · Cited by 90
In Vitro and In Vivo Activities of the Nitroimidazole TBA-354 against Mycobacterium tuberculosis
Upton, A. M., Cho, S., Yang, T., Kim, Y., Wang, Y., Lu, Y., Wang, B., Xu, J., Mdluli, K. E., Ma, Z., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03823-14 · Cited by 89
AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity
Karlowsky, J. A., Kaplan, N., Hafkin, B., Hoban, D. J., & Zhanel, G. G. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00400-09 · Cited by 88
Gurumurthy, M., Mukherjee, T., Dowd, C. S., et al. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08404.x · Cited by 88
Antimicrobial Lexitropsins Containing Amide, Amidine, and Alkene Linking Groups
Anthony, N. G., Breen, D. S., Clarke, J., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070831g · Cited by 86
Locher, H. H., Caspers, P., Bruyère, T., Schroeder, S., Pfaff, P., Knezevic, A., Keck, W., & Ritz, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01831-13 · Cited by 85
Vancomycin and Oritavancin Have Different Modes of Action in Enterococcus faecium
Patti, G. J., Kim, S. J., Yu, T., Dietrich, E., Tanaka, K. S. E., Parr, T. R., Far, A. R., & Schaefer, J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.06.064 · Cited by 82
Ong, V. S., Flanagan, S. D., Fang, E., Dreskin, H. J., Locke, J. B., Bartizal, K. F., & Prokocimer, P. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056697 · Cited by 80
Jacobsson, S., Golparian, D., Alm, R. A., Huband, M. D., Mueller, J. P., Jensen, J. S., Ohnishi, M., & Unemo, M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03090-14 · Cited by 78
Critchley, I. A., Green, L. S., Young, C. L., Bullard, J. M., Evans, R. J., Price, M., Jarvis, T. C., Guiles, J. W., Janjić, N., & Ochsner, U. A. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp041 · Cited by 77
Saravolatz, L. D., Pawlak, J., Johnson, L., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00194-12 · Cited by 76
SQ109, a New Drug Lead for Chagas Disease
Veiga-Santos, P., Li, K., Lameira, L., de Carvalho, T. M. U., Huang, G., Galizzi, M., Shang, N., Li, Q., González‐Pacanowska, D., Hernández-Rodríguez, V., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03972-14 · Cited by 76
Rχ-01, a New Family of Oxazolidinones That Overcome Ribosome-Based Linezolid Resistance
Skripkin, E. A., McConnell, T., DeVito, J., Lawrence, L. E., Ippolito, J. A., Duffy, E. M., Sutcliffe, J. A., & Franceschi, F. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-07 · Cited by 76
Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy
Clark, R. B., Hunt, D. K., He, M., Achorn, C., Chen, C.-L., Deng, Y., Fyfe, C., Grossman, T. H., Hogan, P. C., O’Brien, W. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201467r · Cited by 74
In Vitro Activities of the Rx-01 Oxazolidinones against Hospital and Community Pathogens
Lawrence, L. E., Danese, P. N., DeVito, J. A., Franceschi, F. J., & Sutcliffe, J. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01383-07 · Cited by 72
Stubbings, W., Leow, P., Yong, G. C., Goh, F. Q. Y., Körber-Irrgang, B., Kresken, M., Endermann, R., & Labischinski, H. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00833-10 · Cited by 71
Process R&D of Eravacycline: The First Fully Synthetic Fluorocycline in Clinical Development
Ronn, M., Zhu, Z., Hogan, P. C., Zhang, W., Niu, J., Katz, C. E., Dunwoody, N., Gilicky, O., Deng, Y., Hunt, D. K., et al. (2013) · Organic Process Research & Development · doi:10.1021/op4000219 · Cited by 62
A community-based approach to new antibiotic discovery
Cooper, M. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4706 · Cited by 61
Self-citationCrandon, J. L., & Nicolau, D. P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00033-15 · Cited by 57
Citron, D. M., Tyrrell, K. L., Merriam, C. V., & Goldstein, E. J. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05655-11 · Cited by 56
TD-1792 versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections
Stryjewski, M. E., Potgieter, P. D., Li, Y., Barriere, S. L., Churukian, A., Kingsley, J., Corey, G. R., & for the TD-1792 Investigators Group (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00712-12 · Cited by 55
van Delden, C., Page, M. G. P., & Köhler, T. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02474-12 · Cited by 54
Snydman, D. R., Jacobus, N. V., & McDermott, L. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06257-11 · Cited by 52
β-Lactam Antibiotics Renaissance
Qin, W., Panunzio, M., & Biondi, S. (2014) · Antibiotics · doi:10.3390/antibiotics3020193 · Cited by 49
Rodgers, W., Frazier, A. D., & Champney, W. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02316-12 · Cited by 48
Farrell, D. J., Robbins, M. J., Rhys‐Williams, W., & Love, W. G. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.02.008 · Cited by 47
de Souza, N. J., Gupte, S. V., Deshpande, P. K., Desai, V. N., BHAWSAR, S. B., Yeole, R. D., Shukla, M. C., Strahilevitz, J., Hooper, D. C., Bozdoğan, B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050035f · Cited by 47
Banevicius, M. A., Kaplan, N., Hafkin, B., & Nicolau, D. P. (2013) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000061 · Cited by 47
Bouza, E., & Burillo, A. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.048 · Cited by 46
Alam, Z. A., Wu, X., Mascio, C. T. M., Chesnel, L., & Hurdle, J. G. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01087-15 · Cited by 45
The global challenge of new classes of antibacterial agents: an industry perspective
FERNANDES, P. B. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.06.003 · Cited by 44
Zhou, J., Bhattacharjee, A., Chen, S., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.014 · Cited by 44
Gonzales, F. P., Felgenträger, A., Bäumler, W., & Maisch, T. (2013) · Future Microbiology · doi:10.2217/fmb.13.44 · Cited by 43
López, Y., Tato, M., Espinal, P., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01509-13 · Cited by 42
Putnam, S. D., Sader, H. S., Farrell, D. J., et al. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.08.021 · Cited by 41
Nemonoxacin: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0270-0 · Cited by 41
Speculative strategies for new antibacterials: all roads should not lead to Rome
Shapiro, S. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.27 · Cited by 41
Crandon, J. L., & Nicolau, D. P. (2015) · Pathogens · doi:10.3390/pathogens4030620 · Cited by 41
Rhee, C. K., Chang, J. H., Choi, E. G., et al. (2015) · International Journal of COPD · doi:10.2147/copd.s90948 · Cited by 41
Thiacetazone—avoid like poison or use with care?
Nunn, P. P., Porter, J., & Winstanley, P. (1993) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(93)90096-9 · Cited by 40
Li, K., Wang, Y., Yang, G., Byun, S. Y., Rao, G., Shoen, C. M., Yang, H., Gulati, A., Crick, D. C., Cynamon, M. H., et al. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00026 · Cited by 40
Yin, N., Li, J., He, Y. Q., Herradura, P. S., Pearson, A. L., Mesleh, M. F., Mascio, C. T. M., Howland, K., Steenbergen, J. N., Thorne, G. M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00366 · Cited by 39
Dalhoff, A., Schubert, S., & Ullmann, U. (2005) · Infection · doi:10.1007/s15010-005-8206-y · Cited by 39
Höfer, B., Dantier, C., Gebhardt, K., Desarbre, E., Schmitt‐Hoffmann, A. H., & Page, M. G. P. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks527 · Cited by 39
Discovery and development of surotomycin for the treatment of Clostridium difficile
Knight-Connoni, V., Mascio, C. T. M., Chesnel, L., & Silverman, J. A. (2015) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-015-1714-6 · Cited by 39
Plazomicin: an investigational therapy for the treatment of urinary tract infections
Karaiskos, I., Souli, M., & Giamarellou, H. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1095180 · Cited by 37
Farrell, D. J., Castanheira, M., Sader, H. S., & Jones, R. N. (2010) · Journal of Infection · doi:10.1016/j.jinf.2010.08.010 · Cited by 37
Flamm, R. K., Rhomberg, P. R., Kaplan, N., Jones, R. N., & Farrell, D. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05119-14 · Cited by 37
Sucher, A. J., Chahine, E. B., Cogan, P. S., & Fete, M. G. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015593293 · Cited by 37
Kaplan, N., Awrey, D. E., Bardouniotis, E., Berman, J., Yethon, J. A., Pauls, H. W., & Hafkin, B. (2013) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000063 · Cited by 36
Sattar, A., Thommes, P. A., Payne, L. J., Warn, P. A., & Vickers, R. J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv005 · Cited by 35
Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin
Cheng, M., Ziora, Z. M., Hansford, K. A., Blaskovich, M. A. T., Butler, M. S., & Cooper, M. A. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob42428f · Cited by 34
Self-citationRoss, J. E., Scangarella-Oman, N. E., Flamm, R. K., & Jones, R. N. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00656-14 · Cited by 34
Parsons, J. B., Kukula, M., Jackson, P. D., Pulse, M., Simecka, J. W., Valtierra, D., Weiss, W. J., Kaplan, N., & Rock, C. O. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02307-12 · Cited by 33
Effects of Surotomycin on Clostridium difficile Viability and Toxin Production In Vitro
Bouillaut, L., McBride, S. M., Sorg, J. A., Schmidt, D., Suárez, J. M., Tzipori, S. R., Mascio, C. T. M., Chesnel, L., & Sonenshein, A. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00275-15 · Cited by 32
Bhagwat, S., McGhee, P., Kosowska-Shick, K., Patel, M. V., & Appelbaum, P. C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01150-08 · Cited by 32
Recent Advances in the Inhibition of Bacterial Fatty Acid Biosynthesis
Gerusz, V. J. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45018-6 · Cited by 30
Eravacycline (TP-434) Is Active In Vitro against Biofilms Formed by Uropathogenic Escherichia coli
Grossman, T. H., O'Brien, W., Kerstein, K. O., & Sutcliffe, J. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04967-14 · Cited by 29
So, W., Crandon, J. L., & Nicolau, D. P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00625-15 · Cited by 27
N-Chloro-2,2-dimethyltaurines: a new class of remarkably stable N-chlorotaurines
Wang, L., Khosrovi, B., & Najafi, R. (2008) · Tetrahedron Letters · doi:10.1016/j.tetlet.2008.02.038 · Cited by 27
Melchers, M. J. B., van Mil, A. C. H. A. M., & Mouton, J. W. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04498-14 · Cited by 22
Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial
Citron, D. M., Tyrrell, K. L., Dale, S. E., Chesnel, L., & Goldstein, E. J. C. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02531-15 · Cited by 22
Development of new antibiotics: taking off finally?
Bettiol, E., & Harbarth, S. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14167 · Cited by 22
The potential role of nemonoxacin for treatment of common infections
Huang, C., Lai, C.-C., Chen, Y., & Hsueh, P. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.978288 · Cited by 20
Landman, D., Singh, M., El-Imad, B., et al. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.02.017 · Cited by 18
Stieglitz rearrangement of N,N-dichloro-β,β-disubstituted taurines under mild aqueous conditions
Shiau, T. P., Houchin, A., Nair, S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.109 · Cited by 16
Tsuji, B. T., Harigaya, Y., Lesse, A. J., Forrest, A., & Ngo, D. T. (2013) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000060 · Cited by 12
Why emergency management should be interested in the emergence of antibiotic resistance
Dominey‐Howes, D., Michael, C. A., & Labbate, M. (2014) · UTS ePRESS (University of Technology Sydney) · Cited by 5
Cited by
Pham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T. (2019) · MedChemComm · doi:10.1039/c9md00120d · Cited by 785
Self-citationAntibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Actinomycetes: Still a source of novel antibiotics
Genilloud, O. (2017) · Natural Product Reports · doi:10.1039/c7np00026j · Cited by 465
Antibiotic Discovery: Where Have We Come from, Where Do We Go?
Ribeiro da Cunha, B., Fonseca, L. P., & Calado, C. R. C. (2019) · Antibiotics · doi:10.3390/antibiotics8020045 · Cited by 353
Membrane targeting cationic antimicrobial peptides
Ciumac, D., Gong, H., Hu, X., & Lu, J. R. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.10.103 · Cited by 351
Metadata
- Authors
- Butler, M. S., Blaskovich, M. A., & Cooper, M. A.
- Venue
- The Journal of Antibiotics
- Published
- 2016-06-29
- Volume
- 70
- Issue
- 1
- Pages
- 3-24
- ISSN
- 0021-8820 (ISSN-L)
- 1881-1469
- OpenAlex
- W2463990453
- Cited by
- 349
- References
- 163
- FWCI
- 22.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.